JP2007509117A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007509117A5 JP2007509117A5 JP2006536168A JP2006536168A JP2007509117A5 JP 2007509117 A5 JP2007509117 A5 JP 2007509117A5 JP 2006536168 A JP2006536168 A JP 2006536168A JP 2006536168 A JP2006536168 A JP 2006536168A JP 2007509117 A5 JP2007509117 A5 JP 2007509117A5
- Authority
- JP
- Japan
- Prior art keywords
- thiazol
- pyrimidin
- dimethyl
- phenylamino
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 CC(N1*)=C(c2nc(N*)nc(C)c2*)SC1=O Chemical compound CC(N1*)=C(c2nc(N*)nc(C)c2*)SC1=O 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0324599.0 | 2003-10-21 | ||
| GB0324599A GB0324599D0 (en) | 2003-10-21 | 2003-10-21 | Compound |
| GB0330013A GB0330013D0 (en) | 2003-12-24 | 2003-12-24 | Compound |
| GB0330013.4 | 2003-12-24 | ||
| PCT/GB2004/004465 WO2005042525A1 (en) | 2003-10-21 | 2004-10-21 | Pyrimidin-4-yl-3, 4-thione compounds and their use in therapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007509117A JP2007509117A (ja) | 2007-04-12 |
| JP2007509117A5 true JP2007509117A5 (enExample) | 2007-12-06 |
| JP5164380B2 JP5164380B2 (ja) | 2013-03-21 |
Family
ID=34553788
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006536168A Expired - Fee Related JP5164380B2 (ja) | 2003-10-21 | 2004-10-21 | ピリミジン−４−イル−３，４−チオン化合物及び治療におけるその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7902361B2 (enExample) |
| EP (1) | EP1678171B1 (enExample) |
| JP (1) | JP5164380B2 (enExample) |
| AU (1) | AU2004285745A1 (enExample) |
| BR (1) | BRPI0415759A (enExample) |
| CA (1) | CA2542880A1 (enExample) |
| IL (1) | IL174994A0 (enExample) |
| WO (1) | WO2005042525A1 (enExample) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0012528D0 (en) * | 2000-05-23 | 2000-07-12 | Univ Palackeho | Triterpenoid derivatives |
| GB0219052D0 (en) * | 2002-08-15 | 2002-09-25 | Cyclacel Ltd | New puring derivatives |
| GB0226583D0 (en) * | 2002-11-14 | 2002-12-18 | Cyclacel Ltd | Compounds |
| GB0226582D0 (en) * | 2002-11-14 | 2002-12-18 | Cyclacel Ltd | Anti-viral compounds |
| GB0229581D0 (en) * | 2002-12-19 | 2003-01-22 | Cyclacel Ltd | Use |
| US7572914B2 (en) | 2003-12-19 | 2009-08-11 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| GB0402653D0 (en) * | 2004-02-06 | 2004-03-10 | Cyclacel Ltd | Compounds |
| GB0411791D0 (en) * | 2004-05-26 | 2004-06-30 | Cyclacel Ltd | Compounds |
| WO2006023931A2 (en) | 2004-08-18 | 2006-03-02 | Takeda San Diego, Inc. | Kinase inhibitors |
| CA2576159A1 (en) * | 2004-08-27 | 2006-03-02 | Cyclacel Limited | Purine and pyrimidine cdk inhibitors and their use for the treatment of autoimmune diseases |
| EP1812439B2 (en) | 2004-10-15 | 2017-12-06 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| US20080207594A1 (en) | 2005-05-04 | 2008-08-28 | Davelogen Aktiengesellschaft | Use of Gsk-3 Inhibitors for Preventing and Treating Pancreatic Autoimmune Disorders |
| EP2275096A3 (en) | 2005-08-26 | 2011-07-13 | Braincells, Inc. | Neurogenesis via modulation of the muscarinic receptors |
| EP2258357A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
| US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| GB0520955D0 (en) * | 2005-10-14 | 2005-11-23 | Cyclacel Ltd | Compound |
| GB0520958D0 (en) * | 2005-10-14 | 2005-11-23 | Cyclacel Ltd | Compound |
| WO2007047978A2 (en) | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
| EP2314289A1 (en) | 2005-10-31 | 2011-04-27 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| EP1951307A2 (en) * | 2005-11-11 | 2008-08-06 | Cyclacel Limited | Combination of a cdk-inhibitor and a hdac-inhibitor |
| AU2006315436A1 (en) | 2005-11-15 | 2007-05-24 | Vertex Pharmaceuticals Incorporated | Azaindazoles useful as inhibitors of kinases |
| US7504513B2 (en) | 2006-02-27 | 2009-03-17 | Hoffman-La Roche Inc. | Thiazolyl-benzimidazoles |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| EP2021000A2 (en) | 2006-05-09 | 2009-02-11 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| TW200815418A (en) * | 2006-06-27 | 2008-04-01 | Astrazeneca Ab | New compounds I |
| TW200815417A (en) * | 2006-06-27 | 2008-04-01 | Astrazeneca Ab | New compounds II |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| JP2010505962A (ja) | 2006-10-09 | 2010-02-25 | 武田薬品工業株式会社 | キナーゼ阻害剤 |
| GB0805477D0 (en) * | 2008-03-26 | 2008-04-30 | Univ Nottingham | Pyrimidines triazines and their use as pharmaceutical agents |
| UA103319C2 (en) | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
| JP2012512223A (ja) | 2008-12-18 | 2012-05-31 | エフ．ホフマン−ラ ロシュ アーゲー | チアゾリル−ベンズイミダゾール類 |
| US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| WO2013059634A1 (en) | 2011-10-20 | 2013-04-25 | The Regents Of The University Of California | Use of cdk9 inhibitors to reduce cartilage degradation |
| WO2014069434A1 (ja) * | 2012-10-30 | 2014-05-08 | カルナバイオサイエンス株式会社 | 新規チアゾリジノン誘導体 |
| US10300073B2 (en) | 2014-10-14 | 2019-05-28 | The Regents Of The University Of California | Use of CDK9 and BRD4 inhibitors to inhibit inflammation |
| CN113336746A (zh) * | 2015-08-04 | 2021-09-03 | 常州千红生化制药股份有限公司 | N-(吡啶-2-基)-4-(噻唑-5-基)嘧啶-2-胺类化合物作为治疗性化合物 |
| WO2018005863A1 (en) * | 2016-07-01 | 2018-01-04 | G1 Therapeutics, Inc. | Pyrimidine-based compounds for the treatment of cancer |
| TW202329937A (zh) | 2021-12-03 | 2023-08-01 | 美商英塞特公司 | 雙環胺ｃｋ１２抑制劑 |
| US12084453B2 (en) | 2021-12-10 | 2024-09-10 | Incyte Corporation | Bicyclic amines as CDK12 inhibitors |
| WO2025151517A1 (en) | 2024-01-08 | 2025-07-17 | Wavebreak Therapeutics Limited | Thiazole compounds, compositions and methods of treating disorders associated with missfolding of alpha-synuclein protein |
| WO2026024674A1 (en) | 2024-07-22 | 2026-01-29 | Genesis Therapeutics, Inc. | Methods of treating skp2-associated cancers |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9519275D0 (en) * | 1995-09-21 | 1995-11-22 | Univ Dundee | Substances and their therapeutic use |
| GB9523675D0 (en) * | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
| DE69736351T4 (de) * | 1996-05-08 | 2009-07-23 | Cyclacel Ltd. | Methoden und mittel zur hemmung der cdk4-aktivität |
| US6703395B2 (en) * | 1998-03-04 | 2004-03-09 | Institute Of Experimental Botany Of The Academy Of Sciences Of The Czech Republic | Cyclin dependent kinase inhibitor |
| AU753015B2 (en) * | 1998-03-04 | 2002-10-03 | Cyclacel Limited | Cyclin dependent kinase inhibitor |
| US7045519B2 (en) * | 1998-06-19 | 2006-05-16 | Chiron Corporation | Inhibitors of glycogen synthase kinase 3 |
| GB2361236B (en) * | 2000-03-29 | 2002-04-24 | Cyclacel Ltd | Pyrimidines useful against proliferative disorders |
| MY130778A (en) * | 2001-02-09 | 2007-07-31 | Vertex Pharma | Heterocyclic inhibitiors of erk2 and uses thereof |
| CA2460909A1 (en) * | 2001-09-28 | 2003-04-10 | Cyclacel Limited | N-(4-(4-methylthiazol-5-yl) pyrimidin-2-yl) -n-phenylamines as antiproliferative compounds |
| US7361665B2 (en) * | 2002-07-09 | 2008-04-22 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases |
| GB0226582D0 (en) * | 2002-11-14 | 2002-12-18 | Cyclacel Ltd | Anti-viral compounds |
| GB0226583D0 (en) * | 2002-11-14 | 2002-12-18 | Cyclacel Ltd | Compounds |
| GB0229581D0 (en) * | 2002-12-19 | 2003-01-22 | Cyclacel Ltd | Use |
-
2004
- 2004-10-21 BR BRPI0415759-1A patent/BRPI0415759A/pt not_active IP Right Cessation
- 2004-10-21 WO PCT/GB2004/004465 patent/WO2005042525A1/en not_active Ceased
- 2004-10-21 EP EP04768981.5A patent/EP1678171B1/en not_active Expired - Lifetime
- 2004-10-21 AU AU2004285745A patent/AU2004285745A1/en not_active Abandoned
- 2004-10-21 JP JP2006536168A patent/JP5164380B2/ja not_active Expired - Fee Related
- 2004-10-21 CA CA002542880A patent/CA2542880A1/en not_active Abandoned
-
2006
- 2006-04-11 IL IL174994A patent/IL174994A0/en unknown
- 2006-04-21 US US11/408,463 patent/US7902361B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007520540A5 (enExample) | ||
| JP2008526824A5 (enExample) | ||
| JP2013517283A5 (enExample) | ||
| RU2469036C2 (ru) | Имидазопиридиновые ингибиторы киназ | |
| US7915443B2 (en) | Sulfoximines as kinase inhibitors | |
| CN100355751C (zh) | 2－取代的4－杂芳基－嘧啶、其组合物及其用途 | |
| JP2008500320A5 (enExample) | ||
| JP4988355B2 (ja) | 置換ピペラジン | |
| JP2014511869A5 (enExample) | ||
| US20070021419A1 (en) | 2-Aminophenyl-4-phenylpyrimidines as kinase inhibitors | |
| US7902361B2 (en) | Pyrimidin-4-yl-3, 4-thione compounds and their use in therapy | |
| JP2007504160A5 (enExample) | ||
| JP2006519258A5 (enExample) | ||
| JP2008517945A5 (enExample) | ||
| CN1395566A (zh) | 促肾上腺皮质激素释放因子拮抗剂 | |
| JP2013510876A5 (enExample) | ||
| CN1592743A (zh) | 糖元合成酶激酶3的抑制剂 | |
| JP2017526711A5 (enExample) | ||
| JP2010215644A5 (enExample) | ||
| BG65029B1 (bg) | Триазолови съединения и използването им като допамин-d3-лиганди | |
| CN1642931A (zh) | 用作新颖的组蛋白去乙酰酶抑制剂的磺酰基衍生物 | |
| CN1656073A (zh) | 可用于治疗蛋白激酶依赖性疾病的二芳基脲衍生物 | |
| JP2009526072A5 (enExample) | ||
| JP2008517926A5 (enExample) | ||
| JP2013531055A5 (enExample) |